Characteristics of the COVID-19 patients treated at Gulu Regional Referral Hospital, Northern Uganda: A cross-sectional study

Steven Baguma  
Gulu Regional Referral Hospital

Christopher Okot  
Gulu Regional Referral Hospital

Nelson Alema Onira  
Gulu University, Faculty of Medicine, Department of Anatomy

Paska Apiyo  
Gulu Regional Referral Hospital

Denis Acullu  
Aga Kan Hospital, Mombasa, Kenya

Paska Layet  
Lacor Hospital

Johnson Nyeko Oloya  
Uganda Medical Association, Acholi Branch, Gulu, Uganda

Denis Ochula  
Lamwo Local Government, Uganda

Pamela Atim  
St. Joseph’s Hospital, Kitgum, Uganda

Patrick Odong Olwedo  
Amuru Local Government, Uganda

Francis Pebalo Pebolo  
Gulu University, Faculty of Medicine, Department of Reproductive health

Freddy Wathum Drinkwater Oyat  
Uganda Medical Association, Acholi Branch

Janet Oola  
Nwoya Local Government, Uganda

Judith Aloyo  
Rhites-N, Acholi, Gulu City, Uganda

Eric Nzirakaindi ikoona  
ICAP at Columbia University, Sierra Leone

David Lagoro Kitara (✉ klagoro2@gmail.com)  
Gulu University, Faculty of Medicine, Department of Surgery  
https://orcid.org/0000-0001-7282-5026
Abstract

Background

Coronavirus Disease 2019 (COVID-19) is a severe respiratory disease that results from infection with a new coronavirus (SARS-CoV-2). One of the most critical issues related to the COVID-19 is the high rate of spread, millions of people have been infected around the world, and hundreds of thousands of people have died till now. However, reports from Africa paint a different picture of the SARS-CoV-2 and its effects on the population.

Objectives

The objective of this study was to describe the characteristics of the COVID-19 patients treated at the Gulu Regional Referral Hospital and determine factors associated with COVID-19 manifestations, socio-demographic characteristics, and treatment outcomes from March 2020 to October 2021.

Methods

A retrospective data abstraction of all COVID-19 hospital admissions registered in the Gulu Health Management Information System (HMIS) database and other tools were conducted. The period of study was March 2020 to October 2021. Data that met the inclusion criteria were consecutively abstracted from the Gulu Hospital HMIS database. A local IRB approved the study. SPSS version 25.0 was used for data analysis, and a p-value of 0.05 was considered significant.

Results

Data suggests there were three waves of COVID-19 in Uganda. Those with comorbidities, e.g., Diabetes mellitus 38(5.7%), hypertension 83(12.5%), cardiovascular diseases 58(8.7%), HIV and AIDS 61(9.2%), and other comorbidities such as liver cirrhosis and hepatitis B 40(6.0%) were more susceptible and presented with severe forms of the disease. Antibiotics 662(99.7%), steroids 73(11.0%), vitamin C 564(84.9%), Ivermectin 7(1.1%), and Vitamin D 24(3.6%) were the most used medicines for the treatment of COVID-19 patients. Most COVID-19 patients were unvaccinated 661(99.5%). However, the recovery rate was 632(95.2%). The commonest complications were pneumonia 60(9.0%), chronic fatigue 49(7.4%), acute respiratory distress syndrome (ARDS) 37(5.6%), depression 20(3.0%), systemic infections 19(2.9%), nightmares 15(2.3%) and septic shock 8(1.2%). The Adjusted Odds Ratios (AOR) on factors associated with recovery were treated with steroids AOR=138.835 at 95% CI:12.258-1572.50; p<0.000 and Vitamin D AOR=0.016 at 95% CI:1.902-520.98; p=0.016.

Conclusion

This study showed successful management of COVID-19 patients in low-resource settings with a recovery rate of 95.2%. The admission pattern suggests Uganda had three waves of COVID-19, contrary to the official government position of two. Treatment with steroids and Vitamin D is associated with the recovery of COVID-19 patients. There is a need to conduct more extensive studies on the role played by the two drugs in the successful recovery of COVID-19 patients.
Introduction

Coronavirus Disease 2019 (COVID-19) is a severe respiratory disease that results from infection with a new coronavirus (SARS-COV-2) [1]. One of the most critical issues related to the COVID-19 is the high rate of spread, millions of people have been infected around the world, and hundreds of thousands of deaths till now have been recorded [1]. Patients suffering from different symptoms like fever, dry cough, and fatigue which is usually mild in about 80% of cases, but the more severe cases may progress to develop respiratory distress or respiratory failure, and hence the increased need for intensive care unit (ICU) services [1].

The severity of the disease is related to the age and comorbidities of the infected person; elderly persons are affected more severely with a need for ICU services [2]. The severity of symptoms is also related to its duration, where for mild cases, symptoms may last for two weeks, while for severe cases, it ranges from 3 to 6 weeks [3]. Direct contacts to confirmed cases are the disease’s primary way of spreading because the SARS-COV-2 is transmitted through exhaled air and aerosols [4]. Diagnosis of COVID-19 is conducted using Reverse Transcriptase Polymer Chain Reaction (RT-PCR), Computed Tomography (CT) scan, and blood tests [5]. Supportive treatment is the primary choice for mild cases, including antibiotics, vitamins, trace elements, and antipyretics. At the same time, oxygen therapy with or without mechanical ventilation is introduced and individualized according to each case [6]. Many drugs have been included in clinical trials to act as antiviral agents to the coronavirus disease. Still, no precise results indicate the confirmed effect for any investigated drugs [7-9]. In addition to symptomatic therapy, corticosteroids as an anti-inflammatory agent have been found to play a vital role in the management of severe cases [10].

Thousands of infected patients have recovered from the disease, and this recovery is confirmed by another RT-PCR test or by the absence of the symptoms of the disease for several days. However, no documented study in Uganda provides information on the clinical characterization of COVID-19 cases, treatment outcomes, and factors associated with the clinical presentations and treatment outcomes.

The objective of this study was to describe the characteristics of the COVID-19 patients treated at the Gulu Regional Referral Hospital and determine factors associated with the COVID-19 manifestations, socio-demographic characteristics, and treatment outcomes.

Materials And Methods

Study site

This study was conducted at Gulu Regional Referral Hospital in Northern Uganda, covering admissions of COVID-19 patients from March 2020 to October 2021. Gulu Hospital is a regional referral center for patients from northern Uganda. However, it receives patients from neighboring countries, for example, South Sudan and the Democratic Republic of Congo (DR Congo). It is also a teaching hospital for Gulu University Medical school and many other health training institutions in the region. It is a 394-bed capacity hospital with outpatient and inpatients services estimated at 120,000 patients every year. The Hospital has specialized units such as internal medicine, surgery, pediatrics, reproductive health, TB, HIV, cardiac, chest, dental, dermatology, sickle cell disease, diabetes, hypertension, Ear, Nose and throat, nutrition, accident and emergency, laboratory, ophthalmology, mental health, and orthopedic clinics that consultants manage from Gulu Hospital and Gulu University.

Gulu Regional Referral Hospital was designated by the Ugandan Ministry of Health as a treatment center for COVID-19 patients in March 2020 when COVID-19 was declared a pandemic. As a result, a particular treatment unit for the management of COVID-19 (Gulu CTU) was established with a fully-fledged high dependency unit (HDU), with Oxygen
supply and staff to manage the department. The team leader for the Gulu CTU is a consultant physician who cares for all the COVID-19 patients admitted to the unit. In addition, the Ugandan Ministry of Health and WHO health experts provided additional support for managing the COVID-19 patients at the center using standard protocols developed and practiced in Uganda.

Study design

A retrospective data review and abstraction of all COVID-19 hospital admissions registered in the Gulu Health Management Information System (HMIS) database and other tools were conducted. The period of the review was March 2020 to October 2021. Established by the Ugandan Ministry of Health, HMIS has been the primary source of information on COVID-19 hospital admissions and deaths. COVID-19 notification is compulsory in Uganda, and the emergency operation center at the Uganda National Public Health Institute receives reports on patients admitted to both public and private hospitals with COVID-19.

Sources of data

For the period of this study, COVID-19 patients admitted to Gulu Regional Referral Hospital with COVID-19 were estimated at 900. We included each patient registered in the HMIS database, information on individual's socio-demographic characteristics, self-reported symptoms, signs, comorbidities, COVID-19 Treatment Unit (CTU) admissions, ICU admissions, and ventilatory support, dates of symptom onset, date of hospital admission, date of discharge, duration of the hospital stay, reported circumstances when the disease was contracted, vaccination status and in-hospital outcome (deaths, referrals, and releases/discharges).

HMIS data were accessed, which were already de-identified and publicly available documents. Following ethically agreed principles on open data access, this analysis did not require stringent ethical approval in Uganda as we mainly worked on records with no identifiers included. However, we obtained ethical and administrative licenses from the Gulu Regional Referral Hospital Institution and Ethical Review Committee to access the archived Gulu hospital data on COVID-19 patients.

Selection criteria

Inclusion criteria: The following were the inclusion criteria for the participants (i) Confirmed cases of COVID-19 with RT-PCR results as positive (ii) records of patients 12 years and above (iii) completed information on the chart and other medical tools (iv) admission records

Exclusion criteria: We excluded (i) incomplete records, (ii) records with no RT-PCR results (iii) participants below 12 years.

Selection of records: The medical records for the COVID-19 patients in Gulu Regional Referral Hospital archives were accessed. The choice of the COVID-19 patients' files was conducted consecutively and reviewed by the research team. The selection criteria were applied to each admission file, and a total of 664 files were included in the participating medical records for this research.

Sample size: We determined the sample size for the study population using the selection criteria on the medical records. Six hundred and sixty-four (664) records were included as the sampled population.

Training of research assistants: To obtain excellent and clean information from these COVID-19 patients' medical files, the research team trained the research assistants who were four in number (two medical officers, one clinical
Procedures for data collection: Consecutively registered COVID-19 patients treated at Gulu Regional Referral Hospital with a positive quantitative RT-PCR test result for SARS-CoV-2 admitted to Gulu Hospital were used. SARS-CoV-2 diagnostic tests followed national and international standards. They were done in certified laboratories of Gulu Regional Referral Hospital and Uganda Virus Research Institute (UVRI) as the Ugandan Ministry of Health protocols required.

Variables for the study: The dependent variables for this study were treatment outcomes (alive or dead). The independent variables were the socio-demographics of the COVID-19 patients (age, sex, occupation, religion, tribe, districts, and level of education), comorbidities and treatments used, oxygen saturation at admission, date of discharge from the hospital, duration of hospital stay, disease severity, and others), clinical presentations (signs and symptoms), vaccination status, place of residence and circumstance under which the patient contracted the virus.

Data analysis: The analysis period was from the epidemiological week (starting month and date of March 2020) to the epidemiological week (until month and date of October 2021). The analysis was pre-specified and defined before any reading of the medical data in the records of Gulu Regional Hospital. The sample size was all patients (aged ≥12 years) with COVID-19 diagnosis admitted to the Gulu Regional Referral Hospital and registered in the database between epidemiological weeks of March 2020 and October 2021.

Means, standard deviations, bar graphs, histograms, frequencies, and percentages were used to summarize continuous variables, while frequencies and proportions were calculated for categorical variables. Age-adjusted and sex-adjusted rates for each district by the direct method using the estimated Ugandan population for 2020 as a reference were calculated.

We used the Chi-Square tests at bivariate analysis to observe associations between independent and dependent variables at 95% confidence Intervals. Factors with p-values less or equal to 0.2 were entered into a multivariable regression analysis to determine factors associated with COVID-19 patients treated at Gulu Regional Referral Hospital. However, the Gulu Hospital HMIS data contained much-missing information for some variables, such as reported symptoms, medicines used, and comorbidities. Therefore, we used additional Gulu Regional Referral Hospital records to fill in the missing data. Also, in the post hoc analysis, we evaluated the missing data pattern and conducted a sensitivity analysis via multiple imputations by chained equations, generating 30 imputed datasets. SPSS version 25.0 was used for data analysis, and various imputations were performed utilizing the STROBE guideline recommendations. In addition, Adjusted Odds Ratios (AOR) for independent variables were calculated for the COVID-19 patients treated at the Gulu Regional Referral Hospital from March 2020 to October 2021.

Ethical considerations: This retrospective data review of COVID-19 patients’ medical files at the Gulu Regional Referral Hospital was approved by the Gulu Regional Hospital Institutional, Ethics, and Review Committee.

Results

This study abstracted six hundred and sixty-four (664) medical records of COVID-19 patients treated at the Gulu Regional Referral Hospital from March 2020 to October 2021. Only medical records of COVID-19 patients who met the
inclusion criteria for the study were included. Most COVID-19 patients treated at the Gulu Regional Referral Hospital recovered from the disease with a recovery rate of 632(95.2%) and a mortality of 32(4.8%). In addition, most COVID-19 patients treated at Gulu Regional Referral Hospital were unvaccinated 661(99.5%) for COVID-19.

In figure 1, there were three waves of COVID-19 in Gulu, Northern Uganda, and these were May and September in 2020. In addition, there was a small observable wave in July 2021.

In figure 2, COVID-19 discharges from the CTU of Gulu Regional Referral Hospital mirrored the admission pattern where June, October, and July registered the most releases from the CTU.

Figure 3 shows the peak duration of Hospital stays (days) among COVID-19 patients treated at GRRH as 16 days.
Table 1
Socio-demographic characteristics of COVID-19 patients treated at Gulu Regional Hospital

| Variables                          | Frequency | Percent (%) |
|-----------------------------------|-----------|-------------|
| **Gender**                        |           |             |
| Male                              | 443       | 66.7        |
| Female                            | 221       | 33.3        |
| **Age (years)**                   |           |             |
| <20                               | 41        | 6.2         |
| 20-29                             | 139       | 20.9        |
| 30-39                             | 204       | 30.7        |
| 40-49                             | 151       | 22.7        |
| ≥ 50                              | 129       | 19.4        |
| **Subtotal**                      | 664       | 100.0       |
| **Tribes**                        |           |             |
| Acholi                            | 386       | 59.2        |
| Lango                             | 19        | 2.9         |
| Baganda                           | 70        | 10.7        |
| Madi                              | 22        | 3.4         |
| Others                            | 155       | 23.8        |
| **Subtotal**                      | 652       | 100.0       |
| **Religion**                      |           |             |
| Catholics                         | 95        | 46.3        |
| Protestants                       | 51        | 24.9        |
| Born Again                        | 6         | 2.9         |
| Muslims                           | 44        | 21.5        |
| Others                            | 9         | 4.4         |
| **Subtotal**                      | 205       | 100.0       |
| **The highest level of education attained** | | |
| No formal education               | 64        | 13.7        |
| Primary                           | 43        | 9.2         |
| Secondary                         | 59        | 12.7        |
| Certificates                      | 152       | 32.6        |
| Diploma                           | 65        | 13.9        |
| Variables             | Frequency | Percent (%) |
|-----------------------|-----------|-------------|
| Degrees               | 72        | 15.5        |
| Postgraduate degrees  | 11        | 2.4         |
| **Subtotal**          | **466**   | **100.0**   |
| Occupation            |           |             |
| Business              | 95        | 18.6        |
| Civil Servants        | 97        | 19.0        |
| Health workers        | 47        | 9.2         |
| Teachers              | 7         | 1.4         |
| Uniformed security forces | 27       | 5.3         |
| Peasant Farmers       | 76        | 14.9        |
| Others                | 161       | 31.6        |
| **Subtotal**          | **510**   | **100.0**   |
| Districts             |           |             |
| Agago                 | 9         | 1.4         |
| Amuru                 | 59        | 8.9         |
| Gulu                  | 226       | 34.0        |
| Kitgum                | 50        | 7.5         |
| Lamwo                 | 16        | 2.4         |
| Nwoya                 | 16        | 2.4         |
| Omoro                 | 37        | 5.6         |
| Pader                 | 24        | 3.6         |
| Others                | 227       | 34.2        |
| **Subtotal**          | **664**   | **100.0**   |

In Table 1, most COVID-19 patients treated at the Gulu Regional Referral Hospital from March 2020 to October 2021 were males 443(66.7%), age-group 30-39 years old 204(30.7%); Certificate holders of education 152(32.6%), Acholi 386(59.2%), Catholics 95(46.3%), Civil Servants 97(19.0%) and from Gulu District 226(34.0%).
### Table 2
Symptoms and comorbidities among COVID-19 patients treated at Gulu Regional Hospital

| Symptoms and signs                      | Yes (%) | No (%) |
|----------------------------------------|---------|--------|
| Cough                                  | 331(49.8) | 331(49.8) |
| Tiredness                              | 128(19.3) | 536(80.7) |
| Body aches and pains                   | 192(28.9) | 472(71.1) |
| Sore throat                            | 117(17.6) | 546(82.2) |
| Headache                               | 225(33.9) | 438(66.1) |
| Loss of taste                          | 44(6.6) | 619(93.2) |
| Loss of smell                          | 43(6.5) | 621(93.5) |
| Shortness of breath                    | 171(25.8) | 493(74.2) |
| Loss of speech                         | 20(3.0) | 644(97.0) |
| Vomiting                               | 21(3.2) | 643(96.8) |
| Diarrhea                               | 20(3.0) | 643(96.8) |
| Conjunctivitis                         | 1(0.2) | 662(99.7) |

### Comorbidities

| Comorbidities                                          | Yes (%) | No (%) |
|-------------------------------------------------------|---------|--------|
| Diabetes Mellitus (DM)                                 | 38(5.7) | 626(94.3) |
| Chronic Obstructive Pulmonary Diseases (COPDs)         | 38(5.5) | 656(94.5) |
| Hypertension                                           | 83(12.5) | 581(87.5) |
| Other Cardiovascular Diseases (CVDs), e.g., Stroke, valvular diseases, and heart failures | 58(8.7) | 605(91.3) |
| Obesity                                               | 3(0.5) | 661(99.5) |
| Asthma                                                | 15(2.3) | 648(97.7) |
| Cancers                                               | 4(0.6) | 648(99.4) |
| HIV and AIDS                                          | 61(9.2) | 603(90.8) |
| Other comorbidities (Hepatitis B, Liver diseases, Severe malaria) | 40(6.0) | 624(94.0) |

**Systolic Blood pressure (mmHg)**

| ≤120 | 177(26.7) |
| 121-140 | 298(44.9) |
| >140 | 169(25.5) |

**Diastolic Blood pressure (mmHg)**

| ≤ 80 | 329(49.5) |
| 81-120 | 183(27.6) |
| 121-140 | 132(19.9) |
| Symptoms and signs                                      | Yes (%) | No (%) |
|--------------------------------------------------------|---------|--------|
| Duration of Symptoms (days)                            |         |        |
| 1-7 days                                               | 236(63.1) |        |
| 8-14 days                                              | 107(28.6) |        |
| 15-21 days                                             | 22(5.9) |        |
| 22-28 days                                             | 16(2.4) |        |
| >28 days                                               | 9(2.4) |        |
| Duration of Hospital Stay (Weeks)                      |         |        |
| 0-1                                                    | 318(47.9) |        |
| 2-4                                                    | 300(45.2) |        |
| >4                                                     | 24(3.6) |        |
| Oxygen saturation (SpO₂) of COVID-19 patients at admission |         |        |
| <80                                                    | 9(1.4) |        |
| 80-95                                                  | 85(12.8) |        |
| ≥96                                                    | 403(60.7) |        |
| Clinical presentations                                 |         |        |
| Symptomatic                                            | 509(76.7) |        |
| Asymptomatic                                           | 154(23.2) |        |
| Body Temperature (°C)                                  |         |        |
| ≤ 37.2                                                 | 525(79.1) |        |
| 37.3-38.9                                              | 11(1.7) |        |
| ≥39                                                    | 2(0.3) |        |
| Random blood sugar level (RBS)                         |         |        |
| Normal (≤8 mmol/L)                                     | 11(25.6) |        |
| Abnormal (>8mmol/L)                                    | 32(74.4) |        |
| Fasting Blood Sugar level (FBS)                        |         |        |
| Normal (≤7 mmol/L)                                     | 9(36.0) |        |
| Abnormal (>7mmol/L)                                    | 16(64.0) |        |
| The circumstance of contracting the virus (at Elegu border point with international truck drivers) | 50(7.5) |        |
| Number of COVID-19 patients who died from Gulu Regional Referral Hospital | 32(4.8) |        |
| Number of unvaccinated COVID-19 patients treated at Gulu Hospital | 661(99.5) |        |
Table 3
Medicines used for the treatment of COVID-19 patients at Gulu Regional Referral Hospital

| Medicine used | Frequency (n=664) | Percent (%) |
|---------------|------------------|-------------|
| Hydroxychloroquine | 0                | 0.0         |
| Chloroquine   | 0                | 0.0         |
| Steroids      | 73               | 11.0        |
| Aspirin       | 2                | 0.3         |
| Antibiotics   | 662              | 99.7        |
| Vitamin D     | 24               | 3.6         |
| Vitamin C     | 564              | 84.9        |
| Ivermectin    | 7                | 1.1         |

Table 3 shows medicines used for the treatment of COVID-19 at GRRH: antibiotics 662(99.7%), Vitamin C 564(84.9%), steroids 73(11.0%), Vitamin D 24(3.6%), Ivermectin 7(1.1%), and Aspirin 2(0.3%) in the descending order.

Table 4
Complications in the COVID-19 patients treated at the Gulu Regional Hospital

| Complications                              | Frequency (n=664) | Percent (%) |
|--------------------------------------------|------------------|-------------|
| Depression                                 | 20               | 3.0         |
| Nightmares                                 | 15               | 2.3         |
| Multiple Organ Failure (MOF)               | 5                | 0.8         |
| Acute Respiratory Failure (ARF)            | 30               | 4.5         |
| Pneumonia                                  | 60               | 9.0         |
| Acute Respiratory Distress Syndrome (ARDS) | 37               | 5.6         |
| Acute Liver Injury                         | 2                | 0.3         |
| Acute Cardiac Injury                       | 2                | 0.3         |
| Systemic infections                        | 19               | 2.9         |
| Acute kidney injury                        | 5                | 0.8         |
| Blood clots                                | 3                | 0.5         |
| Chronic fatigue                            | 49               | 7.4         |
| Septic Shock                               | 8                | 1.2         |
| Disseminated Intravascular Coagulation (DIC) | 3                | 0.5         |

In Table 4, complications observed in COVID-19 patients treated in GRRH were Pneumonia 60(9.0%), Chronic fatigue 49(7.4%), acute respiratory distress syndrome (ARDS) 37(5.6%), Acute Respiratory failure 30(4.5%); depression 20(3.0%), systemic infections 19(2.9%), nightmares 15(2.3%) and septic shock 8(1.2%).
Table 5
Crosstabulations among variables in COVID-19 patients treated at Gulu Regional Referral Hospital

| Variables                                                                 | Chi-square | df  | p-value |
|---------------------------------------------------------------------------|------------|-----|---------|
| **Crosstabulations between duration of symptoms (days) and other variables** |            |     |         |
| Symptomatic patients                                                     | 10.301     | 4   | 0.036   |
| Age of patients                                                           | 14.585     | 16  | 0.555   |
| Gender of patients                                                        | 6.284      | 4   | 0.179   |
| The highest level of education attained                                  | 30.42      | 32  | 0.547   |
| **Crosstabulations between Diabetes Mellitus and other variables**        |            |     |         |
| Symptomatic patients                                                     | 5.314      | 1   | 0.021   |
| Age of patients                                                           | 22.66      | 4   | 0.000   |
| Gender of patients                                                        | 0.016      | 1   | 0.901   |
| The highest level of education attained                                  | 32.532     | 8   | 0.000   |
| **Crosstabulations between Chronic obstructive pulmonary diseases (COPDs) and other variables** |            |     |         |
| Symptomatic patients                                                     | 0.014      | 1   | 0.905   |
| Age of patients                                                           | 6.195      | 4   | 0.185   |
| Gender of patients                                                        | 6.346      | 1   | 0.032   |
| The highest level of education attained                                  |            |     |         |
| **Crosstabulations between Other cardiovascular diseases (CVDs) and other variables** |            |     |         |
| Symptomatic patients                                                     | 4.462      | 1   | 0.035   |
| Age of the patients                                                       | 22.562     | 1   | 0.000   |
| Gender of the patients                                                    | 4.996      | 1   | 0.025   |
| The highest level of education attained                                  | 22.451     | 8   | 0.004   |
| **Crosstabulations between Hypertension and other variables**            |            |     |         |
| Symptomatic patients                                                     | 3.045      | 1   | 0.081   |
| Age of the patients                                                       | 35.169     | 4   | 0.000   |
| Gender of patients                                                        | 1.187      | 1   | 0.276   |
| The highest level of education attained                                  | 21.624     | 8   | 0.006   |
| **Crosstabulations between obesity and other variables**                 |            |     |         |
| Symptomatic patients                                                     | 0.173      | 1   | 0.678   |
| Age of patients                                                           | 1.272      | 4   | 0.866   |
| Gender of patients                                                        | 1.512      | 1   | 0.219   |
| The highest level of education attained                                  | 2.083      | 8   | 0.978   |
| Variables                                      | Chi-square | df | p-value |
|------------------------------------------------|------------|----|---------|
| **Crosstabulations between Asthma and other variables** |            |    |         |
| Symptomatic patients                          | 0.0920     | 1  | 0.762   |
| Age of patients                               | 3.7700     | 4  | 0.438   |
| Gender of patients                            | 2.8110     | 1  | 0.094   |
| The highest level of education attained        | 10.3790    | 8  | 0.239   |
| **Crosstabulations between Cancer and other variables** |            |    |         |
| Symptomatic patients                          | 1.2200     | 1  | 0.269   |
| Age of patients                               | 1.7470     | 4  | 0.782   |
| Gender of patients                            | 3.1440     | 1  | 0.076   |
| The highest level of education attained        | 12.6480    | 8  | 0.125   |
| **Crosstabulations between HIV and AIDS and other variables** |            |    |         |
| Symptomatic patients                          | 0.070      | 1  | 0.791   |
| Age of patients                               | 8.515      | 4  | 0.074   |
| Gender of patients                            | 3.646      | 1  | 0.056   |
| The highest level of education attained        | 2.107      | 8  | 0.978   |
Table 6
Characteristics of COVID-19 patients treated at Gulu Regional Referral Hospital

| Variables                                      | Frequency | Percent (%) |
|------------------------------------------------|-----------|-------------|
| Duration of Hospital Stay (Weeks)              |           |             |
| less than a week                              | 56        | 11.6        |
| One                                           | 216       | 44.9        |
| Two                                           | 158       | 32.8        |
| Three                                         | 39        | 8.1         |
| Four                                          | 5         | 1.0         |
| Five                                          | 4         | 0.8         |
| Six                                           | 3         | 0.6         |
| Oxygen saturation Admission (SpO$_2$)         |           |             |
| <80                                           | 7         | 1.5         |
| 80-96                                         | 80        | 16.6        |
| >96                                           | 394       | 81.9        |
| Aspirin                                       |           |             |
| Yes                                           | 2         | 0.4         |
| No                                            | 479       | 99.6        |
| Antibiotics                                   |           |             |
| Yes                                           | 480       | 99.8        |
| No                                            | 1         | 0.2         |
| Vitamin D                                     |           |             |
| Yes                                           | 23        | 4.8         |
| No                                            | 458       | 95.2        |
| Steaming                                      |           |             |
| Yes                                           | 2         | 0.4         |
| No                                            | 479       | 99.6        |
| Vitamin C                                     |           |             |
| Yes                                           | 385       | 80.0        |
| No                                            | 96        | 20.0        |
| Ivermectin                                    |           |             |
| Yes                                           | 7         | 1.5         |
| No                                            | 474       | 98.5        |
| Lemon                                         |           |             |
| Yes                                           | 3         | 0.6         |
| No                                            | 478       | 99.4        |
| Ginger                                        |           |             |
| Yes                                           | 1         | 0.2         |
| No                                            | 480       | 99.8        |
| Garlic                                        |           |             |
| Yes                                           | 2         | 0.4         |
| No                                            | 479       | 99.6        |
| Steroids                                      |           |             |
| Yes                                           | 66        | 13.7        |
| No                                            | 415       | 86.3        |
In Table 6, most COVID-19 patients treated in GRRH were in the hospital for one week 216(44.9%); oxygen saturation (SpO₂) at admission was >96 394(81.9%); did not use Aspirin 479(99.6%), steroids 415 (86.3%), Garlic 480 (99.8%), Lemon 478(99.4%), Ivermectin 474(98.4%), Vitamin D 458(95.2%), and steaming 479 (99.6%) but used Antibiotics 480(99.8%) for treatment.
### Table 7
Factors associated with COVID-19 patients treated at Gulu Regional Referral Hospital CTU

| Variables                                         | Freq (n=664) | Chi-square | df | p-value |
|---------------------------------------------------|--------------|------------|----|---------|
| Duration of symptoms (1-7 days)                    | 236(35.5%)   | 1.101      | 4  | 0.8940  |
| Diabetes Mellitus                                 | 38(5.7%)     | 51.156     | 1  | 0.0000  |
| Chronic obstructive pulmonary diseases (COPDs)     | 8(1.2%)      | 1.041      | 1  | 0.3070  |
| Other Cardiovascular diseases (CVDs)               | 58(8.7%)     | 34.819     | 1  | 0.0000  |
| Hypertension                                      | 83(12.5%)    | 10.807     | 1  | 0.0010  |
| Obesity                                           | 3(0.5%)      | 0.153      | 1  | 0.6960  |
| Asthma                                            | 15(2.3%)     | 0.113      | 1  | 0.7370  |
| Cancers                                           | 4(0.6%)      | 3.565      | 1  | 0.0590  |
| HIV and AIDS                                      | 61(9.2%)     | 6.488      | 1  | 0.0110  |
| Pregnancy                                         | 1(0.2%)      | 1.011      | 1  | 0.8560  |
| Other comorbidities                               | 40(6.0%)     | 37.013     | 1  | 0.0000  |
| Symptomatic                                       | 509(76.7%)   | 2.170      | 1  | 0.1410  |
| Age (>50 years)                                   | 129(19.4%)   | 40.601     | 1  | 0.0000  |
| Gender (Females)                                  | 221(33.3%)   | 7.986      | 1  | 0.0005  |
| The highest level of education attained (graduates)| 72(10.8%)    | 39.213     | 1  | 0.0000  |
| Steroids (1)                                      | 66(13.7%)    | 157.639    | 1  | 0.0000  |
| Aspirin (1)                                       | 2(4.16%)     | 0.124      | 1  | 0.7250  |
| Antibiotics (1)                                   | 480(99.8%)   | 0.062      | 1  | 0.8040  |
| Vitamin D (1)                                     | 23(4.8%)     | 113.521    | 1  | 0.0000  |
| Steaming (1)                                      | 2(0.4%)      | 0.124      | 1  | 0.7250  |
| Vitamin C (1)                                     | 385(80.0%)   | 56.548     | 1  | 0.0000  |
| Ivermectin (1)                                    | 7(1.5%)      | 82.886     | 1  | 0.0000  |
| Garlic (1)                                        | 2(0.4%)      | 0.124      | 1  | 0.7250  |
| Ginger (1)                                        | 1(0.2%)      | 0.062      | 1  | 0.8040  |
| Lemon (1)                                         | 3(0.6%)      | 0.186      | 1  | 0.6660  |
| Oxygen Saturation (SpO₂) <80                      | 7(1.5%)      | 49.799     | 2  | 0.0000  |
| Oxygen Saturation (SpO₂) 80-96                    | 80(16.6%)    | 29.357     | 1  | 0.0000  |
| Oxygen Saturation (SpO₂) >96                      | 394(81.9%)   | 42.962     | 1  | 0.0000  |
| Duration of Stay (Less than one week)             | 56(11.6%)    | 57.690     | 6  | 0.0000  |
| Duration of Stay (One week)                       | 216(44.9%)   | 1.930      | 1  | 0.1650  |
In Table 7, factors associated with COVID-19 patients treated at Gulu Regional Referral Hospital were Diabetes mellitus $\chi^2 = 1.156; \text{df}=1; p<0.0000$; other cardiovascular diseases (CVDs) $\chi^2 = 34.819; \text{df}=1; p<0.0000$; hypertension $\chi^2 = 10.807; \text{df}=1; p=0.0010$; HIV and AIDS $\chi^2 = 6.488; \text{df}=1; p=0.011$; treatment with steroids $\chi^2 = 157.639; \text{df}=1; p<0.0000$; Vitamin D $\chi^2 = 113.521; \text{df}=1; p<0.0000$; vitamin C $\chi^2 = 56.548; \text{df}=1; p<0.0000$; Ivermectin $\chi^2 = 82.886; \text{df}=1; p<0.0000$; Oxygen saturation (SpO$_2$) 80-96 $\chi^2 = 29.357; \text{df}=1; p<0.0000$; Oxygen saturation (<96) $\chi^2 = 42.962; \text{df}=1; p<0.0000$; duration of hospital stay (less than one week) $\chi^2 = 57.690; \text{df}=1; p<0.0000$; duration of hospital stay (two weeks) $\chi^2 = 6.569; \text{df}=1; p=0.010$ and duration of hospital stay (six weeks) $\chi^2 = 4.180; \text{df}=1; 0.041$
Table 8
Multivariable logistic regression showing treatment, Oxygen saturation, and duration of hospital stay for COVID-19 patients treated at GRRH

| Step 1<sup>a</sup> | Steroids (1) | 4.933 | 1.238 | 15.87 | 1 | 0.000 | 138.8350 | 12.258 | 1572.50 |
|-------------------|--------------|-------|-------|-------|---|--------|-----------|--------|--------|
| Aspirin (1)       | -18.74       | 26237.08 | 0.000 | 1 | 0.999 | 0.0000 | 0.0000 | 0.0000 |
| Antibiotics (1)   | 14.645       | 40192.96 | 0.000 | 1 | 1.000 | 2292669.4160 | 0.0000 | 0.0000 |
| Vitamin D (1)     | 3.449        | 1.432 | 5.803 | 1 | 0.016 | 31.4780 | 1.9020 | 520.975 |
| Steaming (1)      | -20.277      | 40192.97 | 0.000 | 1 | 1.000 | 0.0000 | 0.0000 | 0.0000 |
| Vitamin C (1)     | -0.42        | 0.68 | 0.380 | 1 | 0.537 | 0.6570 | 0.1730 | 2.4940 |
| Ivermectin (1)    | 3.504        | 3.438 | 1.039 | 1 | 0.308 | 33.2620 | 0.0390 | 28095.88 |
| Garlic (1)        | 4.933        | 56841.43 | 0.000 | 1 | 1.000 | 138.8330 | 0.0000 | 0.0000 |
| Ginger (1)        | 16.441       | 69616.26 | 0.000 | 1 | 1.000 | 13810166.505 | 0.0000 | 0.0000 |
| Lemon (1)         | -19.579      | 40192.87 | 0.000 | 1 | 1.000 | 0.0000 | 0.0000 | 0.0000 |
| Oxygen (SpO<sub>2</sub> <80) | | 1.124 | 2 | 0.570 |
| Oxygen (80-96)    | 0.174        | 1.502 | 0.013 | 1 | 0.908 | 1.1900 | 0.0630 | 22.6030 |
| Oxygen (>96)      | 0.873        | 1.5 | 0.338 | 1 | 0.561 | 2.3930 | 0.1260 | 45.2910 |
| DoS (<1week)      | 7.140        | 6 | 0.308 |
| DoS (1 week)      | 1.126        | 0.723 | 2.423 | 1 | 0.120 | 3.0820 | 0.7470 | 12.7180 |
| DoS (2 weeks)     | 2.222        | 1.188 | 3.498 | 1 | 0.061 | 9.2290 | 0.8990 | 94.7440 |
| DoS (3 weeks)     | 18.867       | 5359.821 | 0.000 | 1 | 0.997 | 156228723.90 | 0.0000 | 0.0000 |
| DoS (4 weeks)     | 19.883       | 15112.35 | 0.000 | 1 | 0.999 | 431532567.24 | 0.0000 | 0.0000 |
| DoS (5 weeks)     | 15.986       | 19996.241 | 0.000 | 1 | 0.999 | 8765685.4620 | 0.0000 | 0.0000 |

DoS=Duration of Hospital stay.
In Table 8, the Adjusted Odds Ratios (AOR) for factors associated with COVID-19 patients treated at Gulu Regional Referral Hospital. Treatment with Steroids AOR=138.835 at 95% CI: 12.258-1572.50; p<0.000 and Vitamin D AOR=0.016 at 95% CI:1.902-520.98; p=0.016

**Discussions**

The most significant findings were the three waves of COVID-19 in Gulu in Northern Uganda, and these were in May and September of 2020 and July of 2021 (Figure 1, Figure 2, and Figure 3). The third wave of COVID-19 in 2021 was less pronounced (Figure 1, Figure 2, Figure 3). This finding contrasts with the official Ugandan Ministry of Health position on the number of COVID-19 waves Uganda has gone through since the pandemic began in March 2020. The Ugandan Ministry of Health specified two waves of the COVID-19: one in 2020 and another in June 2021. This Ugandan Ministry of Health report is not surprising as regional waves of COVID-19 have been reported in many studies [11, 12, 13, 14]. This finding has implications on how Uganda could respond to the COVID-19 waves as the regional approach to managing and controlling the pandemic has become eminent. The regional occurrence of the COVID-19 wave has advantages in that the Ugandan Ministry of Health could use this information to harness support and allocate resources to effectively manage and control the pandemic at the regional level in different parts of the Country. This may include mass mobilization and sensitization of the population at a regional level to embrace mass vaccination with COVID-19 vaccines now that they are available in the Country. It is expected that this approach could limit the spreading of COVID-19 country-wide and reduce the morbidity and mortality of the coronavirus in Uganda.

**Socio-demographic characteristics of the COVID-19 patients**

Findings from this study show that most COVID-19 patients treated at the Gulu Regional Referral Hospital were males, 30–39-years-old, Acholi, Catholics with certificates as the highest level of education, civil servants, and from Gulu District (Table 1). These socio-demographic characteristics are comparable to previous studies conducted in Northern Uganda, where the most affected people were males and certificates at their highest level of education (Table 1). What is different in this study population is that the most affected age group is a decade older (Table 1) compared to previous studies in Northern Uganda, where most participants were 20–29-years-old [15, 16].

The age factor could be explained by the susceptibility pattern of the COVID-19 among the older population of Northern Uganda and elsewhere. The aging population appears more vulnerable and susceptible. The overall reasons for the susceptibility in the older people in Northern Uganda may not be known for now but perhaps attributable to lifestyles, exposure to multiple risk factors, comorbidities, and immunity problems of the more aging population. As shown in Table 1, the younger age groups were least affected as per the GRRH COVID-19 treatment center’s admission details. However, it could also mean that many of the younger age groups got affected but remained asymptomatic, did not test for COVID-19, did not develop severe disease, and did not get hospitalized with the coronavirus.

Findings from this current study show that nearly one-fourth of the COVID-19 patients treated were asymptomatic, and less than 10% of the patients were below 20 years of age (Table 3). These authors argue that this information
was not wholly new. Similar findings in many studies conducted elsewhere in the world show that younger persons were least susceptible to severe COVID-19 and hospitalization [13, 14, 17].

**Factors associated with the COVID-19 patients treated at the Gulu Regional Referral Hospital**

This report shows that most COVID-19 patients treated for severe COVID-19 and died at the GRRH had comorbidities, for example, Diabetes mellitus, cardiovascular diseases (CVDs) including (Stroke, valvular heart diseases, dysrhythmias, heart failure, and cardiac septal defects), hypertension, and symptomatic cases (Table 2 and Table 3). Many studies have observed similar findings, particularly those with comorbidities [2, 17, 18]. This finding implies that the Ugandan Ministry of Health could adopt the "Enhanced shielding" approach, where persons with comorbidities and the elderly are shielded from the general population to protect them from contracting the COVID-19 virus [12, 19]. These suggestions have implications on the approach the Ugandan health systems could adopt to control the spreading of COVID-19 among the elderly and those with comorbid conditions. The rural structure and relationship between the elderly and younger generation need thorough analysis as the elderly in the rural community live with and together with the young people who provide support and protection to the elderly. The practicality of this approach needs thorough thinking as this new approach may disrupt traditional ways of how people in the African rural communities live. These authors argue that with the lockdown, the economy, and health systems collapsing in many African countries, it is high time government planners came with solutions that allow the economy to be opened but ensure a reduced incidence and prevalence of COVID-19 in communities. One of the recommended approaches was to practice the enhanced shielding approach, which is more favorable to a country's social and economic systems. In addition, there is a need to sensitize and mobilize the population to embrace mass COVID-19 vaccination as vaccines are now available in the country to reduce the incidence of severe diseases which require hospitalization.

**Treatment and complications observed among COVID-19 patients in Gulu Regional Referral Hospital**

Findings from this study show that most COVID-19 patients were treated with antibiotics, vitamin C, steroids, Ivermectin, and vitamin D (Table 3, Table 4, Table 5, Table 6, and Table 7) and the outcomes of the treatment have been encouraging as shown by a very high recovery rate at 95.2% and a statistically significant association with steroid and Vitamin D treatment (Table 8).

In the same study, the most typical complications observed among the COVID-19 patients were pneumonia, acute respiratory distress syndrome (ARDS), systemic infections, septic shock, chronic fatigue, depression, and nightmares (Table 4). These authors argue that there were justified reasons for using antibiotics in treating COVID-19 patients at Gulu Regional Referral Hospital, as many cases developed complications treated with antibiotics.

In addition, the role played by the other drugs in the management of COVID-19 was suggested by scholars and academicians across the world and particularly their use as immune system modulators [17]. To come up with a conclusive decision on the beneficial effects of the two drugs for managing COVID-19 patients at GRRH, formal Randomized controlled Trials will be required.

On the mental health complications observed among the COVID-19 patients treated at the Gulu Regional Referral Hospital, the authors recommend comprehensive mental health support for COVID-19 patients and the follow-up after recovery. Effective management of mental health conditions such as depression relieves the ever-increasing sense of depression and isolation experienced by the COVID-19 patients. If the numbers of mental health cases become widespread, a grassroots approach using trained village health teams (VHTs) would be the recommended approach for handling the problem. Notably, the VHTs should be trained and capable of dealing with COVID-19 related
Psychosocial symptoms in the community. This idea is supported by studies conducted elsewhere in Africa, which suggest a grass-root approach to mental health problems after the lockdown in African [12, 19].

The independent determinants of COVID-19 cases treated at Gulu Regional Referral Hospital: This study showed that the recovery rate from the COVID-19 treated at the Gulu Regional Referral Hospital was 95.2%, yet 99.5% of the COVID-19 patients were unvaccinated (Table 3). Furthermore, this study found the Adjusted Odds Ratios (AOR) for factors associated with COVID-19 patients’ recovery at GRRH were treatment with steroids AOR=138.835 at 95% CI:12.258-1572.50; p<0.000 and Vitamin D AOR=0.016 at 95% CI:1.902-520.98; p=0.016 (Table 8). Statistically significant associations of Vitamin D and steroids with a positive outcome in the treatment and management of COVID 19 patients in our study have also been observed in previous studies [20, 21]. Could these successes be for this center only, or could this apply to diverse settings worldwide? A formal review study in different locations would be required in the long term to determine the effectiveness of the drugs in managing mild and severe cases of COVID-19. Authors recommend global studies on the two drugs to assess their actual effects on the treatment outcomes of COVID-19 patients.

Circumstances under which the coronavirus infected participants

Findings show that most of the circumstances were unknown 581(87.5%), others were congregated situations such overcrowding at Elegu border and interacting with international truck drivers 50(7.5%), Aswa Dam construction workers 12(1.8%) who lived in dormitories, health facility 2(0.3%), persons who nursed a relative with COVID-19 2(0.3%), bars 1(0.2%) and others 16(2.4%). This finding implies that the known source of the COVID-19 infection in Northern Uganda was from international truck drivers and mainly at the Elegu border point. Other sources such as bars, churches, and markets were fewer. Authors argue that regional controls of COVID-19 would be ideal for the East African region, where there is brisk trade among the countries. Therefore, the management and surveillance of international truck drivers as a regional approach would be suitable for controlling the coronavirus, ensuring that COVID-19 testing and management were conducted as per the international protocols across all the East African countries [11].

Strengths and limitations of the study

This study was a retrospective review of datasets from the COVID-19 medical records of Gulu Regional Referral Hospital. The period of the evaluation was from March 2020 to October 2021. The study has limitations on how Gulu Hospital handled records and record keeping. In addition, vital information, for example, weight, height, and BMI of COVID-19 patients, was not recorded due to the emergency handling of the cases at the beginning of the pandemic in March 2020. The missing variables in the Gulu Hospital HMIS records excluded some files from participating in this study. In this, authors have suggested a need for a prospective or longitudinal assessment of the COVID-19 cases in the future, ensuring that all data were measured and recorded accordingly.

This data is vital as it is one of the well-documented completed data for over 664 cases of COVID-19 treated in a Regional Referral Hospital in Uganda. Findings from this study show tremendous and good clinical practices at Gulu Regional Referral Hospital despite the challenges faced during the pandemic.

Generalization of the data from this study

These findings should be cautiously interpreted and generalized only to Regional Referral Hospitals in Uganda. However, they could be similarly observed in many hospitals in African countries with low-resource settings.
Conclusion

This study shows successful management of COVID-19 patients in low resource settings in Gulu Regional Referral Hospital with a recovery rate of 95.2%. The pattern of admission to the Hospital suggests Uganda has experienced three waves of COVID-19, contrary to the official government position of two waves. Treatment of COVID-19 patients with steroids and Vitamin D is associated with recovery of COVID 19 patients. However, there is a need for Randomized Controlled Clinical Trials to determine the actual effects of these drugs in the Treatment of COVID-19 infections.

Declarations

Ethics approval and consent to participate: The Gulu Regional Referral Hospital Institutional and Ethics Committee approved this study, and all participants consented to the study. In addition, the study was conducted following the relevant institutional guidelines and regulations.

Availability of data and material: All datasets supporting the conclusion in this article is within this article and is accessible by a reasonable request to the corresponding author.

Competing interests: All authors declare no conflict of interest.

Funding: Most funding for this study was contributions of individual research members of the Uganda Medical Association (UMA) Acholi branch.

Authors contributions: DLK, ENI, PL, JNO, JA, and FWDO participated in designing the study, SB and DLK were responsible for data abstraction supervision, BS, JA, ENI, and DLK were responsible for data analysis, interpretation, writing, and CO, NAO, WAO, BT, JE, PA, PL, FPP, DA, JNO, FWDO, for revising the manuscript.

Acknowledgment: We acknowledge with many thanks to the support from the administration of Gulu Regional Referral Hospital for the information obtained. Dr. Laban Oketcho, Dr. Anek Janet Schola, Dr. Baguma Steven, and Mr. Dominic Ogwal Savio for the well-collected data from the archives of Gulu Regional Referral Hospital. We also thank Mr. Lawrence Obalim for the data analysis well conducted. In addition, financial support from UMA Acholi branch members, which enabled the team to conduct this study successfully, is most appreciated. In honor of our two fallen colleagues (Co-authors), Dr. Paska Layet and Dr. Oola Janet, may their souls rest in peace!

References

1. Wu Z, McGoogan JMJJ. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. 2020. JAMA.2020;323(13):1239-1242
2. COVID C. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States. February 12-March 16, 2020.
3. Wang D, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;23(11):1061-1069
4. Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in American football players. JAMA. 2017;318(4):360-370
5. Udugama B, Kadhiresan P, Kozlowski HN, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano. 2020;14(4):3822-3835

6. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687-690

7. Gao J, Tian Z, Yang X. Breakthrough Chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73

8. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477

9. Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020. https://doi.org/10.1101/2020.03.17.20037432

10. Fadel R, Morrison A, Vahia A, et al. short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa601.

11. David Lagoro Kitara, Eric Nzirakaindi Ikoona. COVID-19 pandemic, Uganda’s Story. Pan Afr Med J. 2020; 35:51

12. David Lagoro Kitara, Eric Nzirakaindi Ikoona. Proposed strategies for easing COVID-19 lockdown measures in Africa. Pan Afr Med J. 2020; 36(179):10.11604/pamj.2020.36.179.24194.

13. Marco Vinceti, Tommaso Filippini, Kenneth J. Rothman, Silvia Di Federico & Nicola Orsini. The association between first and second wave COVID-19 mortality in Italy. BMC Public Health. 2021;21(2069).

14. Andrey N Petrov, Mark Welford, Nikolay, Golosov John DeGroote, Michele Devlin, Tatiana Degai, and Alexander Savelyev. The second wave of the COVID-19 pandemic in the Arctic: regional and temporal dynamics. International Journal of Circumpolar Health. 2021; 80(1). https://doi.org/10.1080/22423982.2021.1925446.

15. David Lagoro Kitara, Omar Karlsson. The effects of economic stress and urbanization on driving behaviors of Boda-boda drivers and accidents in Gulu, Northern Uganda: a qualitative view of drivers. Pan Afr Med J, 2020;36:47. Doi:10.11604/pamj.2020.36.47.21382.

16. Joyce Ayugi, George Ndagijimana, Stanley Luyima, David Lagoro Kitara. Breast cancer awareness and downstaging practices among adult women in the Gulu City Main Market, Northern Uganda: A cross-sectional study. Research Square. 2021. DOI: https://doi.org/10.21203/rs.3.rs-1136303/v1

17. Kirenga B, Muttamba W, Kayongo A, et al. Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda. BMJ Open Resp Res 2020;7:e000646. doi:10.1136/ bmjresp-2020-000646

18. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20

19. David Lagoro Kitara, Eric Nzirakaindi Ikoona. A proposed framework to limit post-lockdown community transmission of COVID-19 in Africa. Pan Afr Med J. 2021;38:303. DOI: 10.11604/pamj.2021.38.303.24008. eCollection 2021

20. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:458–64.

21. Naushad Ali. Role of vitamin D in preventing COVID-19 infection, progression, and severity. Journal of Infection and Public Health. 2020;13(10):1373-1380

Annex I: Informed Consent

Title: Characterization of COVID-19 patients admitted at Gulu Regional Referral Hospital, Gulu, Northern Uganda, from March 2020 to October 2021
Principal Investigator: Prof. David Kitara Lagoro

This qualitative component will occur at most health facilities and in the nine districts in the Acholi subregion in Northern Uganda.

The purpose: Since the outbreak of COVID-19, there has been no global consensus on how the virus has to be controlled and managed. North America and western Europe have demonstrated that eradicating the disease requires a safe and effective vaccine, simultaneous and multiple public health approaches. We need to assess the views of the health managers and policymakers, such as the district task force members, on what they feel should be done to curb the spread of the virus in the region.

We want to invite you to participate in this qualitative research. Participation is entirely voluntary and decides if you wish to participate in it or not. The need to read the following information carefully and ask if there is anything unclear is paramount and if you would like more information.

The benefit of this study: There are no direct benefits to you. We aim to determine the opinions of the population of northern Uganda to COVID-19 spread, prevention, and control. Findings may shed light on how we could inform policy which may further allow us to undertake future strategies and interventions to educate and reduce the spread of COVID-19 in our communities.

Confidentiality: Informed consent will be obtained from each participant before this study. Confidentiality will be maintained during and after the study. Every participant's personal information will be de-identified and given a unique code identifier for the analysis. Only the Principal Investigator will have access to the data for the study. At the end of the project, all the data will be submitted to Gulu University, Faculty of Medicine, Department of Surgery for archiving.

Voluntary Participation: Your participation in this study is voluntary. You are free to withdraw from the study at any time without any adverse consequences. You have the right not to answer any question you wish not to. You are free to ask any questions regarding the information you gave on this questionnaire.

I fully understand the aims of the study explained to me in a language that I know and have been allowed to ask questions that have been answered and give my consent to participate in the study.

Name of study participant................................signature..........................Date.................................

Name of Interviewer....................................Signature..........................Date.................................

If you need additional information on this research, contact the following persons.

1. Dr. Baifa Arwinyo (Chair Ethics and Research Committee, Gulu Regional Referral hospital on 0782047694
2. Dr. Elima James (Gulu Hospital Director) on 0772540956
3. Prof. David Kitara Lagoro (Lead Researcher-Gulu University, Faculty of Medicine) on 0772524474 and email: klagoro@gmail.com or klagoro2@gmail.com

Figures
Figure 1: The pattern of COVID-19 admission into the Gulu Treatment Unit (CTU)

In figure 1, there were three waves of COVID-19 in Gulu, Northern Uganda, and these were May and September in 2020. In addition, there was a small observable wave in July 2021.

Figure 1

The pattern of COVID-19 admissions to the Gulu Treatment Unit (CTU). In figure 1, there were three waves of COVID-19 in Gulu, Northern Uganda, and these were May and September in 2020. In addition, there was a small observable wave in July 2021.
Figure 2: The pattern of discharges of COVID-19 patients treated at the CTU of Gulu Regional Referral Hospital

In figure 2, the pattern of COVID-19 discharges from the CTU of Gulu Regional Referral Hospital mirrored the admission pattern where June, October, and July registered the most numbers of releases from the CTU.

Figure 2

The pattern of discharges of COVID-19 patients treated at the CTU of Gulu Regional Referral Hospital. In figure 2, COVID-19 discharges from the CTU of Gulu Regional Referral Hospital mirrored the admission pattern where June, October, and July registered the most releases from the CTU.
Figure 3: Duration of Hospital stays (days) of COVID-19 patients treated at Gulu Regional Referrals Hospital

Figure 3 shows the peak duration of Hospital stays (days) among COVID-19 patients treated at GRRH at 16 days.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryMaterialS1.docx